Expertise & Services


The pathology core provides comprehensive, rapid molecular pathology services ranging from standard histology to custom work such as TMA construction, antibody validation, and genomic analysis including CISH and FISH, in addition to providing the pathology expertise required for scoring and interpretation of results.


Our molecular pathology and applied genomics core is supported by a world class team of molecular pathologists and offers a broad range of analytical services to the public and private sectors including:


  • Single staining
  • Double-staining

Immunohistochemistry biomarker evaluation

In situ immunofluorescence

In situ hybridization

  • FISH
  • CISH

In situ Toxicology Analysis

In situ Proximity-ligation Analysis

Tissue Micro Array (TMA) construction

High-throughput scanning

Image storage service
Remote VPN access

Digital Image Analysis

Whole Mount Tissue Analysis

  • Murine tissue
  • Human Prostate
  • Human Pancreas

Laser-Capture Micro-dissection (LCM)

Manual Macro Dissection (LMD)


A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.


2016 Step Up team

Step Up Challenge fundraiser: February 25, 2018

The annual Step Up Challenge, raising funds for Prostate Cancer Canada, takes place in Vancouver on Sunday February 25. Click here to sponsor our relay team as they climbs 379 floors. Click here to volunteer to help with the event.

It's a Snow Day poster

It's A Snow Day at Mt. Seymour: March 9

Mt. Seymour is hosting It's A Snow Day, a fundraiser for Prostate Cancer Foundation BC, on Friday March 9. The event will include slope time, a reception, and a silent auction. Click here for more details including how to register, donate and/or sponsor.




Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.